Article Details
Retrieved on: 2025-03-14 13:51:45
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the approval of SYCUME® (teprotumumab), a groundbreaking IGF-1R antibody for thyroid eye disease (TED), reflecting advancements in autoimmune disease treatment and epidemiology by Innovent Biologics in collaboration with Eli Lilly. The development addresses unmet needs in TED, primarily impacting those with thyroid-related conditions.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here